Elevance Health (NYSE:ELV) Director Buys 1,000 Shares of Stock

Elevance Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Elevance Health Director Ramiro Peru bought 1,000 shares for $383,860, increasing his direct stake by 9.17% to 11,908 shares.
  • The company reported quarterly EPS of $6.99, beating the $4.71 consensus estimate, and revenue of $50.44 billion, above forecasts.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $458.91; Elevance also declared a quarterly dividend of $1.72 per share.
  • Interested in Elevance Health? Here are five stocks we like better.

Elevance Health, Inc. (NYSE:ELV - Get Free Report) Director Ramiro Peru acquired 1,000 shares of the business's stock in a transaction that occurred on Thursday, November 19th. The stock was bought at an average cost of $383.86 per share, for a total transaction of $383,860.00. Following the completion of the purchase, the director directly owned 11,908 shares in the company, valued at $4,571,004.88. This represents a 9.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Elevance Health Stock Performance

Shares of NYSE:ELV traded up $11.17 during midday trading on Friday, hitting $401.33. The company's stock had a trading volume of 279,985 shares, compared to its average volume of 1,584,557. The stock has a market capitalization of $86.71 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.91 and a beta of 0.63. The stock's 50 day simple moving average is $416.40 and its 200 day simple moving average is $376.69. Elevance Health, Inc. has a fifty-two week low of $274.84 and a fifty-two week high of $450.69. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.71 by $2.28. The company had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business's revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.03 EPS. As a group, research analysts anticipate that Elevance Health, Inc. will post 29.16 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health's dividend payout ratio (DPR) is currently 29.34%.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Field & Main Bank boosted its position in Elevance Health by 1.3% during the 2nd quarter. Field & Main Bank now owns 1,883 shares of the company's stock worth $728,000 after acquiring an additional 25 shares during the last quarter. Simplicity Wealth LLC raised its holdings in shares of Elevance Health by 1.3% in the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company's stock valued at $754,000 after purchasing an additional 25 shares during the last quarter. Tranquilli Financial Advisor LLC raised its holdings in shares of Elevance Health by 1.3% in the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company's stock valued at $805,000 after purchasing an additional 26 shares during the last quarter. Mather Group LLC. lifted its position in shares of Elevance Health by 3.5% in the third quarter. Mather Group LLC. now owns 766 shares of the company's stock worth $298,000 after purchasing an additional 26 shares in the last quarter. Finally, 55 North Private Wealth LLC lifted its position in shares of Elevance Health by 4.5% in the third quarter. 55 North Private Wealth LLC now owns 598 shares of the company's stock worth $233,000 after purchasing an additional 26 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ELV has been the topic of several research analyst reports. Wall Street Zen raised shares of Elevance Health from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $451.00 price objective on shares of Elevance Health in a report on Friday, October 23rd. Argus upgraded Elevance Health from a "hold" rating to a "buy" rating and set a $510.00 price objective on the stock in a research report on Wednesday. UBS Group upped their price target on Elevance Health from $460.00 to $523.00 and gave the company a "buy" rating in a research note on Thursday, October 22nd. Finally, Barclays raised their price target on Elevance Health from $469.00 to $472.00 and gave the company an "overweight" rating in a report on Thursday, October 22nd. Sixteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Elevance Health presently has a consensus rating of "Moderate Buy" and an average price target of $458.91.

View Our Latest Research Report on ELV

About Elevance Health

(Get Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elevance Health Right Now?

Before you consider Elevance Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.

While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines